表紙
市場調査レポート

世界における幹細胞治療市場の将来展望

Global Stem Cell Therapy Market Future Outlook

発行 KuicK Research 商品コード 334104
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界における幹細胞治療市場の将来展望 Global Stem Cell Therapy Market Future Outlook
出版日: 2015年07月06日 ページ情報: 英文 300 Pages
概要

当レポートでは、世界における幹細胞治療市場について調査し、世界市場の分析、幹細胞研究の動向、幹細胞市場のダイナミクス、世界市場のダイナミクス、企業・罹患率・フェーズごとによる幹細胞治療薬の臨床パイプライン、臨床・前臨床パイプライン上にある幹細胞治療薬、市販の幹細胞治療薬、および主要企業のプロファイルなどについて考察しています。

第1章 幹細胞のイントロダクション

第2章 幹細胞の分類

  • 分化する能力の基礎
  • 複製起点の基礎
  • ソースの基礎

第3章 幹細胞移植の各種類

  • 自己幹細胞移植
  • 同種異系幹細胞移植
  • 同系幹細胞移植

第4章 幹細胞治療のメカニズム

第5章 幹細胞研究の動向

  • 心血管疾患向け幹細胞治療薬
  • 癌治療向け幹細胞治療薬
  • 中枢神経系疾患向け幹細胞治療薬
  • 眼科疾患向け幹細胞治療薬
  • 代謝疾患向け幹細胞治療薬
  • 胃腸 (消化管) 疾患向け幹細胞治療薬

第6章 世界の幹細胞市場分析

  • 市場の現況
  • 世界の幹細胞治療薬パイプライン概要

第7章 世界の幹細胞市場ダイナミクス

  • 好ましい要因
  • 商業化の問題

第8章 幹細胞市場の将来の展望

第9章 世界の幹細胞治療薬の臨床パイプラン・企業、適応症およびフェーズ別

  • 研究中
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第III相
  • 承認済み

第10章 市販の幹細胞治療薬の考察

  • 脂肪幹細胞治療薬 (Adipocell)
  • 血管由来の細胞前駆体治療薬(VesCell)

第11章 臨床パイプラインにおいて中止された幹細胞治療薬

第12章 競合情勢

企業リスト

目次

Stem cells are specialized cells that can differentiate into other cells without losing their identity. They have been found to be present in animals as well as humans and most of the work has been done on mice. Investigators have found that stem cells are part of repair system and helps in maintaining the normal bodily functions. They divide to give rise to two cells out of which one remains the same while other differentiates into the required cell type. They can replenish throughout the life-time and they could repair damaged organs in order to prevent further damage. They are also influenced by external cues due to which they could be converted into different cell type. It is expected that investigators would be able to make new discoveries that would allow them to assign new properties to stem cells. More research is required in this segment to fully understand the properties of stem cells.

Investigators are trying to decipher stem cells biochemical and biophysical properties so that they could develop them as a therapeutic commodity. Their ability to convert into different cell types could be used for developing regenerative medicines. Organ regeneration at laboratory levels have been achieved but it will take some time for developing fully functional transplantable organ. Investigators have found they could be used for various oncological applications. Modified stem cells could be used for curing cancer and some success has been achieved in past years. Their utility in cardiovascular diseases has been noted as they have ability to regenerate damaged cardiac muscles. In neural disorders like Alzheimer's disease and Parkinson's disease their role is being studied as presently available therapeutics have modest efficacy with short-lived effects.

Innovations in pharmaceutical industry seem to be the main driving force for the development of stem cell therapies. Investigators have been able to identify different stem cell sources which offers them large base for developing new therapies. Their customizability and appropriate usage is expected to help them to discover new pharmacological properties that may have high commercialization potential. As a result, large numbers of stem cell therapies are entering in clinical trials across the globe. They are at different stages of development and likely to be introduced in global market in coming years. This will help the stem cell therapy developers to generate significant revenues in coming years. However, this scenario may take few years to materialize but some stem cell therapies have already entered in market which are in clinical practice for past years.

As per recent research report "Global Stem Cell Therapy Market Future Outlook " published by KuicK Research, advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years.

"Global Stem Cell Therapy Market Future Outlook" Report Highlight:

  • Global Stem Cell Market Analysis
  • Trends in Stem Cell Research
  • Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges
  • Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase
  • Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies
  • Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies
  • Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication
  • Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell® & VesCell™)

Table of Contents

1. Introduction to Stem Cells

2. Classification of Stem Cells

  • 2.1 Basis of Ability to Differentiate
  • 2.2 Basis of Origin
  • 2.3 Basis of their Source

3. Different Type of Stem Cell Transplants

  • 3.1 Autologous Stem Cell Transplants
  • 3.2 Allogeneic Stem Cell Transplants
  • 3.3 Syngeneic Stem Cell Transplants

4. Mechanism of Stem Cell Therapy

5. Trends in Stem Cell Research

  • 5.1 Stem Cell Therapy for Cardiovascular Diseases
  • 5.2 Stem Cell Therapy for Cancer Treatment
  • 5.3 Stem Cell Therapy for Central Nervous System Disorders
  • 5.4 Stem Cell Therapy for Ophthalmic Disorders
  • 5.5 Stem Cell Therapy for Metabolic Disorders
  • 5.6 Stem Cell Therapy for Gastrointestinal Diseases

6. Global Stem Cell Market Analysis

  • 6.1 Current Market Scenario
  • 6.2 Global Stem Cell Therapies Pipeline Overview

7. Global Stem Cell Market Dynamics

  • 7.1 Favorable Factors
  • 7.2 Commercialization Challenges

8. Stem Cell Market Future Prospects

9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Clinical
  • 9.4 Phase-I
  • 9.5 Phase-I/II
  • 9.6 Phase-II
  • 9.7 Phase-III
  • 9.8 Registered

10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication

  • 10.1 Adipose Stem Cell Therapy (Adipocell®)
  • 10.2 Angiogenic Cell Precursor Therapy (VesCell™)

11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline

  • 11.1 No Development Reported
  • 11.2 Discontinued
  • 11.3 Suspended

12. Competitive Landscape

  • 12.1 Aldagen
  • 12.2 AlloCure
  • 12.3 Anterogen
  • 12.4 Arteriocyte Medical Systems
  • 12.5 Athersys Inc.
  • 12.6 Baxter Healthcare Corporation
  • 12.7 Bioheart
  • 12.8 Cambridge Enterprise Ltd
  • 12.9 Celyad
  • 12.10 Celgene Corporation
  • 12.11 Cellerant Therapeutics
  • 12.12 Cellonis Biotechnologies
  • 12.13 CellPraxis
  • 12.14 Chiesi
  • 12.15 Caladrius
  • 12.16 Cryopraxis
  • 12.17 Cytori Therapeutics
  • 12.18 Gamida Cell
  • 12.19 Genexine
  • 12.20 Geron
  • 12.21 Intrexon Corporation
  • 12.22 K-STEMCELL
  • 12.23 Lifecells LLC
  • 12.24 Medipost
  • 12.25 Medistem Panama
  • 12.26 Mesoblast
  • 12.27 Novartis
  • 12.28 Nuo Therapeutics
  • 12.29 Ocata Therapeutics
  • 12.30 OmniCyte Ltd
  • 12.31 OncoMed
  • 12.32 Osiris Therapeutics
  • 12.33 Pharmicell
  • 12.34 Pluristem Therapeutics
  • 12.35 Promethera Biosciences
  • 12.36 ReNeuron
  • 12.37 Stem Cell Sciences (SCS)
  • 12.38 Stem Cells
  • 12.39 Stemedica Cell Technologies
  • 12.40 TCA Cellular Therapy
  • 12.41 TheraVitae
  • 12.42 TiGenix
  • 12.43 Vericel Corporation

List of Figures

  • Figure 1-1: Properties of Stem Cells
  • Figure 1-2: Utility of Stem Cells
  • Figure 1-3: Benefits of Stem Cells
  • Figure 1-4: Limitations of Stem Cells
  • Figure 2-1: Type of Stem Cells on the Basis of Ability to Differentiate
  • Figure 2-2: Type of Stem Cells on the Basis of Origin
  • Figure 2-3: Types of Stem Cells on the Basis of their Source
  • Figure 2-4: Different Sources of Autologous Stem Cell
  • Figure 3-1: Different Stem Cell Transplants
  • Figure 4-1: Source of Hematopoietic Stem Cells
  • Figure 4-2: Mechanism of Stem Cells Blood Related Diseases
  • Figure 4-3: Mechanism of Skin treatment by Stem Cells
  • Figure 4-4: Mechanism of Stem Cell Diabetes Treatment
  • Figure 5-1: Relevant Type of Stem Cells for CVS
  • Figure 5-2: Proposed Mechanism of Stem Cell Activity
  • Figure 6-1: Difference between Autologous & Autogenic HSCTs
  • Figure 6-2: Global Stem Cell Market Opportunity (US$ Billion), 2015-2020
  • Figure 6-3: Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-4: Global Stem Cell Therapies Clinical Pipeline by Phase (Number), 2015
  • Figure 6-5: No Development Reported Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-6: No Development Reported Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-7: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase (%), 2015
  • Figure 6-8: Discontinued Global Stem Cell Therapies Clinical Pipeline by Phase (Number), 2015
  • Figure 7-1: Global Stem Cell Market Favorable Parameters
  • Figure 7-2: Global Stem Cell Market Commercialization Challenges
  • Figure 12-1: Anterogen - Clinical Pipeline
  • Figure 12-2: Arteriocyte Medical Systems Clinical Pipeline
  • Figure 12-3: Bioheart-Clinical Pipeline
  • Figure 12-4: Celgene-Clinical Pipeline
  • Figure 12-5: Cellerant-Therapeutics Clinical Pipeline
  • Figure 12-6: Caladrius-Clinical Pipeline
  • Figure 12-7: Gamida Cell- Clinical Pipeline
  • Figure 12-8: Genexie-Clinical Pipeline
  • Figure 12-9: Mesoblast Clinical Pipeline
  • Figure 12-10:OncoMed-Clinical Pipeline
  • Figure 12-11: Osiris Therapeutics- Clinical Pipeline
  • Figure 12-12: Pharmicell-Clinical Pipeline
  • Figure 12-13: Promethera- Clinical Pipeline
  • Figure 12-14: ReNeuron-Clinical Pipeline
  • Figure 12-15: Stem Cell-Clinical Pipeline
  • Figure 12-16: Vericel-Clinical Pipeline

List of Tables

  • Table 2-1: Difference between Embryonic, Adult & Induced Stem Cells
  • Table 3-1: Comparison between Different Types of Stem Cell Transplants
  • Table 3-2: Few Autologous Stem Cell Therapies under Development
  • Table 4-1: Different Stem Cells used for Skin Treatment
Back to Top